MAIA Biotechnology, Inc. 8-K

What Happened
MAIA Biotechnology, Inc. announced it prepared and presented a poster titled “Sustained Response and Long-Term Therapeutic Benefits Beyond Treatment Cessation in Abstract NSCLC Relapsed-Patients Treated with Ateganosine and ICI in the THIO-101 Trial” at the European Lung Cancer Congress (ELCC) in Copenhagen, Denmark on March 27, 2026. The poster was posted to the company’s website the same day and was filed as Exhibit 99.1 with the company’s Form 8-K. The filing notes the poster contains forward-looking statements and advises investors not to place undue reliance on them.

Key Details

• Poster presented at ELCC (Copenhagen) on March 27, 2026 and posted to MAIA’s website the same day.
• Topic: THIO-101 trial results in relapsed non-small cell lung cancer (NSCLC) patients treated with ateganosine plus an immune checkpoint inhibitor (ICI).
• Exhibit filed: Poster included as Exhibit 99.1 in the Form 8-K.
• Disclosure is made under Regulation FD; material clinical information was publicly disseminated at the conference.

Why It Matters
This 8-K is a clinical update rather than a financial report—investors get public access to new trial data and company messaging about THIO-101’s potential in relapsed NSCLC. Because the information was released under Regulation FD and filed with the SEC, it ensures broad public disclosure of the poster content. The filing contains forward-looking language, so while the poster may influence perceptions of MAIA’s clinical progress, it does not change the company’s financial statements or guarantee future outcomes.